on NanoViricides, Inc. (NASDAQ:NNVC)
NanoViricides Receives "Outperform" Rating in New Analyst Report
On July 8, 2026, NanoViricides, Inc., a company focused on developing antiviral drugs, announced an "Outperform" rating from an independent analyst report. Prepared by Noble Capital Markets, Inc., the report assigns a target price of $6.00 for the company's stock, citing promising ongoing programs. It highlights the potential of their lead antiviral drug, NV-387, which targets various viral infections including RSV and Influenza.
The report maintains that estimates and projections are solely the analyst's opinions, independent of NanoViricides' guidance. NanoViricides has been working with Noble Capital to enhance investor relations.
In addition, a "Fireside Chat" interview featuring President Dr. Anil Diwan was released, elucidating the company's progress and the effectiveness of NV-387 against emerging viral variants. This is crucial amid a global resurgence of diseases like Measles and Monkeypox, for which NanoViricides seeks to provide viable treatments.
R. P.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all NanoViricides, Inc. news